GSK halts development of new PI, brecanavir

This article is more than 18 years old. Click here for more recent articles on this topic

Glaxo SmithKline announced today that it is terminating the development of brecanavir, a new protease inhibitor licensed from Vertex, because of problems in developing an oral formulation of the drug.

The drug had reached phase II trials and early results in treatment-naïve and treatment-experienced patients appeared promising. However, today the company said in a press release: “This decision has been taken as we have been unable to develop a viable oral dosage formulation capable of delivering the desired drug levels in patients with multi-drug-resistant HIV.”

People currently receiving brecanavir in clinical trials will be moved over to other therapies as appropriate.

Glossary

formulation

The physical form in which a drug is manufactured or administered. Examples of formulations include tablets, capsules, powders, and oral and injectable solutions. A drug may be available in multiple formulations.

oral

Refers to the mouth, for example a medicine taken by mouth.

treatment-naive

A person who has never taken treatment for a condition.

treatment-experienced

A person who has previously taken treatment for a condition. Treatment-experienced people may have taken several different regimens before and may have a strain of HIV that is resistant to multiple drug classes.

toxicity

Side-effects.

The decision to discontinue development is a blow to Glaxo SmithKline’s hopes to develop a portfolio of new anti-HIV drugs. Last year the company was forced to abandon development of an agent in a new class of drugs, a chemokine antagonist, because of serious liver enzyme elevations and liver toxicity in three patients.